Next-generation oncolytic virus therapies for solid tumors.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy for the treatment of cancer. Its proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute, and is designed to selectively replicate within and destroy tumor cells while sparing normal tissue. The company was founded by Two River Group, chaired by Arie Belldegrun, M.D., FACS — the team behind Kite Pharma and Allogene Therapeutics — and is focused on developing next-generation oncolytic viruses engineered for superior potency and immune engagement in solid tumors.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2024
Jan 2021
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
